The current state of the art and future trends in RAS-targeted cancer therapies

Abstract

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state. Some of these inhibitors have proven efficacy in patients with KRAS^G12C-mutant cancers and have become practice changing. The excitement associated with these advances has been tempered by drug resistance, which limits the depth and/or duration of responses to these agents. Improvements in our understanding of RAS signalling in cancer cells and in the tumour microenvironment suggest the potential for several novel combination therapies, which are now being explored in clinical trials. Herein, we provide an overview of the RAS pathway and review the development and current status of therapeutic strategies for targeting oncogenic RAS, as well as their potential to improve outcomes in patients with RAS-mutant malignancies. We then discuss challenges presented by resistance mechanisms and strategies by which they could potentially be overcome.

The RAS oncogenes are among the most common drivers of tumour development and progression but have historically been considered undruggable. The development of direct KRAS inhibitors has changed this paradigm, although currently clinical use of these novel therapeutics is limited to a select subset of patients, and intrinsic or acquired resistance presents an inevitable challenge to cure. Herein, the authors provide an overview of the RAS pathway in cancer and review the ongoing efforts to develop effective therapeutic strategies for RAS-mutant cancers. They also discuss the current understanding of mechanisms of resistance to direct KRAS inhibitors and strategies by which they might be overcome.

Key points

• Owing to intrinsic and extrinsic factors, KRAS and other RAS isoforms have until recently been impervious to targeting with small-molecule inhibitors.

• Inhibitors of the KRAS^G12C variant constitute a potential breakthrough in the treatment of many cancer types, particularly non-small-cell lung cancer, for which such an agent has been approved by the FDA.

• Several forms of resistance to KRAS inhibitors have been defined, including primary, adaptive and acquired resistance; these resistance mechanisms are being targeted in studies that combine KRAS inhibitors with inhibitors of horizontal or vertical signalling pathways.

• Mutant KRAS has important effects on the tumour microenvironment, including the immunological milieu; these effects must be considered to fully understand resistance to KRAS inhibitors and when designing novel treatment strategies.

Introduction

RAS signalling has an essential role in driving normal physiological cellular proliferation, and dysregulation of this signalling pathway commonly occurs during tumorigenesis^1,2. Indeed, alterations in components of this pathway, particularly those in the RAS proteins themselves, have far-reaching consequences in many cancers^3,4. Thus, over the past few decades, substantial efforts have been made to drug RAS proteins, the central mediators of this pathway⁵. In 2021, the decades of research finally achieved some clinical success, with the approval of the KRAS^G12C inhibitor sotorasib for a specific subset of patients with non-small-cell lung cancer (NSCLC). In this Review, we provide an overview of the RAS pathway in cancer, focusing on the role of mutant KRAS. We discuss why mutant KRAS was, until recently, unamenable to pharmacological inhibition, and detail current strategies for therapeutic targeting of KRAS. We then consider mechanisms of resistance to KRAS inhibition and ways in which they might be overcome. Finally, we discuss the future of targeted therapy for RAS-mutant cancers, with a particular focus on combinations that could move beyond transient responses towards cure.

The RAS pathway

The RAS–RAF–MEK–ERK mitogen-activated kinase signalling (MAPK) pathway is activated by most, if not all, growth factor, cytokine and immunological receptors, as well as by many integrins and chemokine receptors^2,5. The canonical pathway module features a receptor tyrosine kinase (RTK) coupled to the RAS–RAF–MEK–ERK cascade. The RAS family GTPases, KRAS, NRAS and HRAS, cycle between GTP-loaded ‘on’ and GDP-loaded ‘off’ states^4,6, involving the action of RAS-guanine nucleotide exchange factors (RAS-GEFs) and RAS-GTPase-activating proteins (RAS-GAPs), respectively. During this activation–inactivation process, the conformations of two regions in the RAS protein, termed the ‘switch 1’ and ‘switch 2’ domains, are altered⁷. As detailed further below, these structural changes, particularly in switch 2, proved crucial for the eventual development of RAS inhibitors.

RAS-GEFs can promote the release of either GDP or GTP from RAS proteins in vitro; however, because the cellular GTP:GDP ratio is ~10 (refs.^8,9), they catalyse GDP-to-GTP exchange in cells. SOS1 and SOS2 (SOS1/2), the major RAS-GEFs activated by RTKs and cytokine receptors, bind via C-terminal proline-rich motifs to the SRC homology 3 (SH3) domains of the adapter protein GRB2 (ref.¹⁰). GRB2 can simultaneously bind via its SH2 domain to phosphorylated tyrosine motifs (pY-X-N-X) in various other proteins, including RTKs, scaffolding adapters (such as SHC, GAB, FRS and IRS proteins) and/or the SOS1-activating non-receptor protein tyrosine phosphatase SHP2, to precisely coordinate the RAS-GEF activity of SOS1/2 and thus RAS activation (Fig. 1). Subsequently, GTP-loaded RAS can interact with RAS-binding domains (RBDs) in downstream effector proteins, including the RAF family kinases ARAF, BRAF and RAF1 (also known as CRAF). Thus, active RAS recruits RAF proteins to the cell membrane, where they interact with membrane lipids, dimerize and are activated⁴. The active RAF kinases phosphorylate and activate MEK1 and/or MEK2, which in turn phosphorylate and activate ERK1 and/or ERK2 (Fig. 1). ERK1/2 can then phosphorylate multiple cytosolic and nuclear proteins, including other kinases (such as RSK, MSK and MNK), transcription factors and cytoskeletal proteins². Other important RAS effectors include the catalytic p110 subunit of phosphatidylinositol 3-kinase (PI3K), Ral guanine nucleotide dissociation stimulator (RAL-GDS) and the Rho guanine nucleotide exchange factor TIAM1 (refs.^4,6). The RAS effectors mediate diverse effects on cellular phenotype, for example, activating the cell-cycle machinery in dividing cells or driving the differentiation of various other cell types.

Fig. 1. The RAS signalling pathway and therapeutic approaches to target this pathway in cancer.

Numerous direct inhibitors have been developed to target mutant RAS proteins, either in their inactive, GDP-bound state (‘KRAS-off inhibitors’) or in their active, GTP-bound state (‘RAS-on inhibitors’). Many of these inhibitors are being evaluated in clinical trials. The RAS signalling pathway has many upstream and downstream mediators, which are attractive targets for combination therapies with RAS inhibitors to improve antitumour responses and to mitigate intrinsic and acquired resistance; agents that have been combined with direct KRAS inhibitors in preclinical or clinical studies are listed. Therapeutic cancer vaccines against mutant RAS epitopes and small interfering RNA (siRNA)-based approaches that target oncogenic RAS isoforms are also under ongoing development. ILK, integrin-linked kinase; mTORC2, mTOR complex 2; PI3K, phosphatidylinositol 3-kinase; RTK, receptor tyrosine kinase.

Wild-type RAS isoforms have intrinsic, albeit weak, hydrolytic (GTPase) activity and can, therefore, self-inactivate; however, RAS-GAPs stimulate this activity dramatically^11–14. Indeed, the GAPs increase RAS GTPase activity fivefold relative to the intrinsic rate¹². Hence, within cells, normal hydrolysis of RAS-bound GTP depends on GAPs such as neurofibromin (NF1) or Ras GTPase-activating protein 1 (RASA1; also known as p120RASGAP), which contain SH2/SH3 domains or other binding motifs and are, therefore, also recruited to activated RTKs and scaffolding adapters as a crucial feedback mechanism to switch off RAS signalling.

As alluded to previously, abnormalities in components of the RAS pathway, including activating RAS mutations, are common across a diverse range of malignancies (Fig. 2). In cells with such alterations, aberrant RAS signalling ultimately leads to activation of several key transcription factors, which in turn drive several hallmarks of cancer, including increased cell-cycle entry, metabolic reprogramming, cell growth and survival, and angiogenesis^1,3,4.

Fig. 2. The prevalence of KRAS, NRAS and HRAS mutations across cancer types.

Mutations in the RAS genes are common in gastrointestinal and lung cancers, with KRAS mutations comprising most of these mutations, but also occur more rarely in various other cancer types. The data shown in the graph are from the cBioportal TCGA and MSK-IMPACT cohorts (available via the cBioPortal for Cancer Genomics)^17,18.

RAS mutations in cancer

Mutations that affect RAS–RAF–MEK–ERK pathway components, including various RTKs, SHP2, NF1, RAS proteins, RAF family members or MEK1/MEK2, can result in aberrant activation of this pathway and oncogenesis (Fig. 1). RAS mutations or amplifications are among the most frequent abnormalities in human cancers⁶: KRAS is most often altered, especially in solid tumours; NRAS mutations are present in melanoma and many haematological malignancies; and HRAS mutations mainly occur in bladder, thyroid, cervical, and head and neck cancers¹⁵ (Fig. 2). The MSKCC IMPACT and AACR Project GENIE clinical sequencing cohorts (data available via the cBioPortal for Cancer Genomics)^16–18 provide the most accurate estimates of the prevalence of mutational events in patients with cancer; each dataset indicates that ~20% of all malignancies have a RAS abnormality. Overall, ~17% of solid tumours have KRAS mutations, including ~90% of pancreatic, ~50% of colon and ~25% of lung adenocarcinomas^16,17 (Fig. 2). Indeed, KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours¹⁷. The activating missense KRAS mutations that occur in ~25% of NSCLCs^19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK²⁴. Despite much effort, however, RAS gene products (HRAS, NRAS and KRAS) have been extremely challenging targets for drug development^25,26.

Almost all cancer-associated RAS mutations (~95%) affect codon 12, 13 or 61, and lead to a markedly increased basal RAS-GTP:RAS-GDP ratio and constitutive activation of RAS effectors^4,6. Mutations at glycine residue 12 (G12) of KRAS are most common, with glycine 13 (G13) being the next most frequently affected residue in KRAS²⁷. Recurrent KRAS codon 12 mutations most commonly result in G12C, G12V or G12D substitutions, which account for 40%, 19% and 15% of KRAS mutations in NSCLCs, respectively. Although much attention has been focused on KRAS^G12C mutations in NSCLCs (prevalence of ~14%), these mutations are not unique to NSCLC and also occur less commonly in colorectal cancers (CRCs; 3%) and pancreatic ductal adenocarcinomas (PDACs; 1%)²⁸. Unlike other clinically actionable genomic alterations found in NSCLCs (such as EGFR and ALK aberrations), KRAS mutations, particularly KRAS^G12C and KRAS^G12V, are strongly associated with smoking^29–31.

Various KRAS mutations might have different prognostic and/or predictive implications in patients with NSCLC. In patients with refractory metastatic NSCLC treated with molecularly targeted therapy (either erlotinib, vandetanib, bexarotene plus erlotinib or sorafenib) in the BATTLE trial, tumours with KRAS^G12C or KRAS^G12V mutation were associated with poorer outcomes, in terms of progression-free survival (PFS), than those with wild-type KRAS or other KRAS mutations³². However, another study that involved patients from the pre-immunotherapy era found no statistically significant differences in overall survival (OS) between patients with metastatic NSCLC harbouring various KRAS codon 12 and 13 mutations³³. Moreover, a study evaluating the outcomes of patients treated with immune-checkpoint inhibitors (ICIs) revealed improved PFS in those with KRAS^G12C mutations relative to those with non-G12C mutations³⁴. Together, these findings highlight the need for further investigation to clarify the prognostic and predictive roles of distinct KRAS mutations.

Although mutations in KRAS and other oncogenic drivers, such as EGFR and ALK, are typically mutually exclusive, co-mutations in the tumour-suppressor genes STK11, TP53 or CDKN2A/CDKN2B are frequently found in KRAS-mutant tumours³⁵. Patients in the KRAS–STK11 co-mutation group can be subdivided into KEAP1-wild-type or KEAP1-mutant subgroups, and KEAP1 can also be co-mutated with KRAS in the absence of STK11 mutations; each of these co-mutation patterns is associated with resistance to treatment in preclinical models and seems to confer an unfavourable prognosis and poor treatment responses in patients with NSCLC receiving ICIs with or without chemotherapy^36–41. The lack of responsiveness to ICIs in patients with KRAS-mutant NSCLCs harbouring co-mutations in STK11 and/or KEAP1 has been attributed to alterations in immunophenotype in the tumour microenvironment (TME)⁴⁰. Furthermore, preclinical data indicate that IGF1–IGF1R signalling functions as a bypass pathway in KRAS–STK11 co-mutated cells following molecularly targeted therapy using the MEK inhibitor trametinib⁴². Therefore, characterization of the entire molecular landscape of KRAS-mutant NSCLCs will be crucial to devise optimal therapeutic strategies.

Biochemical properties of mutant KRAS

Amplification of wild-type KRAS can contribute to the pathogenesis of oesophagogastric, colorectal, ovarian and endometrial tumours⁴³. In these settings, KRAS remains under the control of its canonical regulators. By contrast, RAS mutants were once viewed as being ‘locked’ in the GTP-bound ‘on’ state, impervious to GAP-stimulated or intrinsic GTP hydrolysis, and hence undruggable. However, detailed structural and biochemical analyses of various RAS mutants associated with cancer and ‘RASopathies’, which are developmental disorders caused by germline mutations in the RAS−MAPK pathway⁴⁴, have revealed subtle but important differences in their intrinsic and GAP-catalysed GTPase activity, intrinsic and SOS1/2-stimulated GDP–GTP exchange, and effector-binding profiles^14,45–49. For example, KRAS mutants vary in their intrinsic GTPase activity, with KRAS^G12C and, to a lesser extent, KRAS^G12D having greater activity than other variants. KRAS^G12C-mediated GTP hydrolysis is, however, refractory to (and might even be inhibited by) RAS-GAPs, whereas some other KRAS variants (G12D, G12A, G12R and G12V) might remain responsive to GAPs⁵⁰. Even with GAP stimulation, the GTPase activity of KRAS^Q61L and KRAS^G61H is limited⁵¹. Wild-type RAS-GTP has a >10-fold higher affinity for RAF than for p120RASGAP (at least in vitro)⁵². Moreover, structural studies suggest that RAS-GTP cannot undergo hydrolysis when it is bound to RAF^52–55, although data from single turnover kinetic studies contest this notion⁴⁵. Thus, for GAP-responsive RAS mutants, the hydrolytic rate in cells probably equates to the GAP-stimulated rate. A study published in 2021 indicates that regulator of G protein signalling 3 (RGS3), an atypical GAP that lacks the characteristic catalytic arginine finger, can enhance the GTPase activity of mutant KRAS⁵⁶. This important finding implies that susceptibility to the action of RGS3, instead of intrinsic GTPase activity, is the predominant determinant of the extent to which a given KRAS mutant occupies the GDP-bound state in cells — and thus the potential sensitivity of the cells to current ‘KRAS-off’ inhibitors, which bind to the inactive conformation of mutant KRAS⁵⁶.

Mutations also affect the binding affinity of RAS proteins for their effectors. For example, KRAS^G12D binds to the RAF1-RBD approximately fivefold less strongly than wild-type RAS does⁴⁶. The biological implications of these biochemical differences were unclear until recently. In 2020, Zafra et al.⁵⁷ used high-fidelity CRISPR-based engineering to create mouse models of KRAS-mutant lung, pancreas and colon cancers, and found that different KRAS mutations had distinct effects on the transformation of colonic and pancreatic epithelial cells. Moreover, data indicate that the pathogenetic effects of different KRAS mutations, and the susceptibility of KRAS mutants to direct or indirect therapeutic targeting, depend on cell lineage and the presence of specific co-mutations, as well as the precise biochemical effects of specific allelic variants^57–60.

The difficulty of drugging KRAS

The several-decade struggle to drug KRAS and other RAS isoforms^25,61 reflects challenges posed by three key biochemical features: first, the picomolar affinity of RAS proteins for GTP⁶²; second, the high intracellular concentrations of GTP (~500 nM)⁹; and third, the absence of a deep or pharmacologically actionable small-molecule-binding pocket in the RAS proteins. The success of small-molecule drugs that compete with ATP binding (ATP-competitive kinase inhibitors) is well known. However, the first two features — the high GTP-binding affinity and concentrations — make the analogous development of GTP-competitive RAS inhibitors unfeasible, if not impossible. Although intracellular ATP levels are typically ~5 mM, the K_M for ATP of typical protein kinases is in the 10–100 µM range⁶³, enabling drugs that bind with high picomolar or low nanomolar affinity to compete effectively at pharmacologically achievable concentrations. By contrast, overcoming the picomolar affinity of RAS for GTP would require small molecules with unprecedented binding properties. Moreover, the GTP-binding site of the KRAS protein varies between specific KRAS mutants, such as the G12C, G12D, G12V, G13D and Q61H variants⁶⁴, which further complicates KRAS inhibitor design. Consequently, first-generation direct KRAS inhibitors all bind to inactive, GDP-bound mutant KRAS (KRAS-off inhibitors)^65–68. More recently, however, ‘KRAS-on’ inhibitors that target active KRAS-GTP, such as RM-018 (ref.⁶⁹), have been developed (Fig. 1 and Table 1).

Table 1.

Selected KRAS-directed therapies

Strategy and target	Agent	Phase of development
Mutant-specific direct KRAS inhibitors
KRASG12C	Sotorasib (AMG 510)	Approved for previously treated advanced-stage KRASG12C-mutant NSCLC; further clinical trials ongoing (NCT03600883, NCT04185883, NCT04303780, NCT04933695, NCT04625647, NCT05398094, NCT05074810, NCT04380753, NCT05311709, NCT05054725, NCT05400577, NCT05180422, NCT04667234, NCT05198934, NCT05374538, NCT05313009, NCT05118854, NCT05273047, NCT05251038, NCT04892017, NCT04959981, NCT04720976)
	Adagrasib (MRTX849)	Clinical trials (NCT03785249, NCT04330664, NCT04613596, NCT04793958, NCT04685135, NCT05162443, NCT05375994, NCT05263986, NCT04975256, NCT05178888, NCT04418661)
	D-1553	Clinical trials (NCT04585035, NCT05383898, NCT05379946)
	JDQ443	Clinical trials (NCT04699188, NCT05132075, NCT05358249, NCT05329623)
	RG6330 (GDC-6036)	Clinical trials (NCT04449874, NCT03178552)
	LY3537982	Clinical trials (NCT04956640)
	BI 1823911	Clinical trials (NCT04973163)
	JAB-21822	Clinical trials (NCT05009329, NCT05194995, NCT05002270, NCT05276726, NCT05288205)
	JNJ-74699157 (ARS-3248)	Clinical trials (NCT04006301)
	MK-1084	Clinical trials (NCT05067283)
	ARS-1620	Preclinical studies
	ARS-853	Preclinical studies
	RM-018	Preclinical studies
	RMC-6291	Preclinical studies
KRASG12D	MRTX1133	Preclinical studies
	JAB-22000	Preclinical studies
	RMC-9805 (RM-036)	Preclinical studies
KRASG13C	RMC-8839	Preclinical studies
KRASG12V	JAB-23000	Preclinical studies
KRASMULTI	JAB-23400	Preclinical studies
Pan-RAS inhibitors
RASMULTI	RMC-6236	Clinical trials (NCT05379985)
	BBP-454	Preclinical studies
SOS1 inhibitors
SOS1	BI 1701963	Clinical trials (NCT04973163, NCT04111458, NCT04975256, NCT04835714, NCT04627142)
	RMC-5845	Preclinical studies
	BAY-293	Preclinical studies
	BI-3406	Preclinical studies
	SDGR5	Preclinical studies
SHP2 inhibitors
SHP2	RMC-4630 (SAR442720)	Clinical trials (NCT03634982, NCT05054725, NCT04418661, NCT03989115, NCT04916236, NCT04185883)
	TNO155	Clinical trials (NCT03114319, NCT04000529, NCT04294160, NCT04956640, NCT04330664, NCT04292119, NCT04699188, NCT04185883)
	GDC-1971	Clinical trials (NCT04449874)
	JAB-3068	Clinical trials (NCT03518554, NCT03565003, NCT04721223)
	JAB-3312	Clinical trials (NCT04045496, NCT04121286, NCT04720976, NCT05288205)
	SHP099	Preclinical studies
	RMC-4550	Preclinical studies
RAS degraders
KRASG12C	LC-2 (PROTAC)	Preclinical studies
KRASG12C, KRASG12D, KRASG12V and KRASQ61H	K27-SPOP	Preclinical studies
RAS toxins
Pan-RAS	RRSP–DTB	Preclinical studies
Adoptive cell therapy
KRASG12V	Specific TCRs	Clinical trials (NCT04146298)
KRASG12D	Specific TCRs	Preclinical studies
Cancer vaccines
KRASG12C, KRASG12D, KRASG12V and KRASG13D	mRNA-5671/V941	Clinical trials (NCT03948763)
KRASG12C, KRASG12V, KRASG12D, KRASG12A, KRASG13D or KRASG12R	Mutant KRAS-targeted long-peptide vaccine	Clinical trials (NCT04117087)
KRASG12C, KRASG12V, KRASG12D or KRASG12R	mDC3/8-KRAS vaccine	Clinical trials (NCT03592888)
KRASG12D or KRASG12R	ELI-002 2P	Clinical trials (NCT04853017)
KRAS siRNAs
Various mutant KRAS mRNAs	Various nanoparticle-based technologies	Preclinical studies
KRASG12D mRNA	iExosomes	Clinical trials (NCT03608631)

NSCLC, non-small-cell lung cancer; PROTAC, proteolysis targeting chimera; siRNA, small interfering RNA; TCR, T cell receptor.

The KRAS^G12C breakthrough

The lack of an adequate binding pocket for small molecules posed an equally daunting challenge for RAS-targeted drug discovery. In 2013, the laboratory of K. Shokat achieved a major breakthrough in KRAS targeting. Capitalizing on a unique disulfide-fragment-based chemical library approach, they screened 480 tethering compounds coupled to a cysteine-attacking nucleophile and identified compounds that bound covalently and selectively to KRAS^G12C-GDP⁷⁰. X-ray crystallography revealed binding of the hit compounds to an expanded switch 2 pocket created by displacement of glutamine 61 (Q61) by the mutant cysteine in KRAS^G12C-GDP, and coupling of the nucleophile warhead to that cysteine⁷⁰. Accordingly, inhibitors of this type are KRAS^G12C specific; therefore, they do not affect RAS signalling in non-malignant cells^65,70–72 and, at least theoretically, have a low risk of on-target, off-tumour toxicities. Extensive medicinal chemistry efforts to refine the initial lead compounds resulted in the development of ARS-853, ARS-1620 and, ultimately, all clinical KRAS^G12C inhibitors, including sotorasib and adagrasib^{65–68,70,73,74} (Fig. 1).

The mechanism of inhibition by these compounds implies that a substantial proportion of cellular KRAS^G12C must at least transiently reside in the GDP-bound state. As alluded to previously, data indicate that conversion of KRAS^G12C-GTP to KRAS^G12C-GDP primarily reflects the action of RGS3, although GTP hydrolysis would eventually occur owing to the preserved intrinsic GTPase activity in this mutant. Consequently, RAS-GEFs essentially compete with KRAS^G12C-off inhibitors for binding to KRAS^G12C-GDP. Direct evidence for this conclusion is provided by the finding that second-site mutations that decrease nucleotide exchange, such as Y32S, enhance ARS-853-mediated inhibition of KRAS^G12C-GTP formation; secondary mutations such as Y40A, N116H and A146V, which enhance intrinsic nucleotide exchange and thus result in decreased levels of KRAS^G12C-GDP, had the opposite effect⁶⁵. Further evidence has been provided by genetic or pharmacological inhibition of SOS1 or SHP2. For example, inhibitors of SOS1 reduce the activity of this key RAS-GEF and have demonstrated preclinical efficacy in combination with trametinib in KRAS^G12C-mutant and KRAS^G13D-mutant cell lines⁷⁵, suggesting the potential for synergy when combined with KRAS-off inhibitors.

KRAS^G12C inhibitors in the clinic

Initial first-in-human data from 22 patients with advanced-stage KRAS^G12C-mutant solid tumours receiving sotorasib in the phase I/II CodeBreaK 100 study indicated single-agent activity, including a partial response (PR) in one of six patients with NSCLC⁷⁶. Subsequent data from 129 patients enrolled in the phase I part of this trial demonstrated an objective response rate (ORR) of 32.2%, a disease control rate (DCR) of 88.1% and a median PFS of 6.3 months in 59 patients with advanced-stage NSCLC, as well as a 7.1% ORR, a 73.8% DCR and a median PFS of 4.0 months among 42 patients with CRC⁶⁰. Responses also occurred in patients with melanoma, pancreatic, endometrial or appendiceal cancer⁶⁰. The phase II portion of CodeBreaK 100, which involved 124 evaluable patients with previously treated advanced-stage KRAS^G12C-mutant NSCLC, demonstrated an ORR of 37.1%, a median duration of response (DoR) of 11.1 months, median PFS of 6.8 months and median OS of 12.5 months⁶⁷. These impressive results led to the 2021 FDA accelerated approval of sotorasib for this indication. An updated analysis encompassing 174 patients with NSCLC included in the phase I and II parts of CodeBreaK 100 revealed that 1-year OS was 50.8% and 2-year OS was 30.3%⁷⁷. Furthermore, data from the PDAC cohort of CodeBreaK 100 showed an ORR of 21.1% and a DCR of 84.2% in a heavily pretreated patient population (n = 38)⁷⁸. However, similar success was not seen in the CRC cohort (n = 62), in which the ORR was 9.7%⁷⁹. Sotorasib is currently being compared with docetaxel in the second or later line treatment of advanced-stage KRAS^G12C-mutant NSCLC (after progression on both an ICI and platinum-based doublet chemotherapy, individually or combined) in the phase III CodeBreaK 200 trial, with a primary end point of PFS⁸⁰. Trials in the first-line setting are also ongoing (NCT04933695), and a multitude of trials are testing sotorasib alone or in combination with other agents across various settings in NSCLC and beyond (Table 1 and Supplementary Table 1).

Adagrasib, the second KRAS^G12C inhibitor to enter clinical testing, received FDA breakthrough therapy designation for previously treated advanced-stage KRAS^G12C-mutant NSCLC on the basis of data from the phase I/II KRYSTAL-1 trial^68,81. Data from this trial, presented at the European Society for Medical Oncology (ESMO) Congress 2021, demonstrated a 96% DCR in this setting: 23 (45%) of 51 evaluable patients had a PR, and an additional 26 had stable disease⁸¹. In the phase I/Ib part of KRYSTAL-1, the median PFS of 16 patients with KRAS^G12C-mutant NSCLC receiving adagrasib at the recommended phase II dose was 11.1 months and the median DoR was 16.4 months⁸². Updated data from 116 patients with previously treated NSCLC included in a registrational phase II cohort of KRYSTAL-1 showed an ORR of 42.9%, a DCR of 79.5%, median DoR of 8.5 months, median PFS of 6.5 months, median OS of 12.6 months and estimated 1-year OS of 50.8% with adagrasib⁸³. Additionally, in the subgroup of patients with previously treated, stable brain metastases (n = 33), the intracranial ORR was 33.3%⁸³. In another phase II cohort of KRYSTAL-1, ORRs of 50% and 35% have been reported for ten evaluable patients with KRAS^G12C-mutant PDAC and 17 with other KRAS^G12C-mutant non-CRC gastrointestinal cancers, respectively, with a DCR of 100% in both groups; median PFS was 6.6 months in the PDAC group⁸⁴. In 45 evaluable patients with CRC harbouring KRAS^G12C mutations who were also enrolled in KRYSTAL-1, adagrasib monotherapy resulted in an ORR of 22% and a DCR of 87%, with a median DoR of 4.2 months and median PFS of 5.6 months; in an additional 28 patients who received adagrasib in combination with cetuximab, the ORR was 43%, with a 100% DCR⁸⁵. Numerous trials of adagrasib in various contexts are ongoing (Table 1 and Supplementary Table 1).

Several other KRAS^G12C inhibitors that act through a similar mechanism have entered clinical development more recently (Table 1 and Supplementary Table 1). GDC-6036 (also known as RG6330) is being tested alone and in combination with various monoclonal antibodies and kinase inhibitors as well as the SHP2 inhibitor GDC-1971 in a phase I trial involving patients with various advanced-stage KRAS^G12C-mutant solid tumours (NCT04449874). JDQ443, another covalent irreversible KRAS^G12C-off inhibitor, has also entered clinical testing after demonstrating favourable pharmacokinetic characteristics and promising antitumour activity in preclinical models⁸⁶. A phase I/II trial is evaluating JDQ443 as monotherapy and in combination with TNO155 (another SHP2 inhibitor) and/or tislelizumab (an anti-PD-1 antibody) in patients with KRAS^G12C-mutant NSCLC, CRC or other advanced-stage solid tumours (KontRASt-01; NCT04699188). In parallel, a confirmatory phase III trial comparing JDQ443 with docetaxel in patients with previously treated KRAS^G12C-mutant NSCLC is planned (KontRASt-02; NCT05132075), and a phase I/II platform study testing various other JDQ443-based combination therapies across tumour types has been initiated (KontRASt-03; NCT05358249). LY3537982, a selective KRAS^G12C inhibitor, is also in phase I clinical development for KRAS^G12C-mutant solid tumours, both alone and in combination with various other agents (NCT04956640). Other KRAS^G12C-targeted compounds in phase I/II trials include D-1553, JNJ-74699157, BI 1823911, JAB-21822 and MK-1084 (Supplementary Table 1) and numerous other inhibitors of KRAS^G12C and/or other KRAS mutants are in preclinical development (Table 1).

The dramatic conceptual advance provided by the development of KRAS^G12C inhibitors cannot be overstated. Nevertheless, the potential for long-term benefit from KRAS^G12C inhibitors, at least as single agents, is modest at best; several primary and acquired mechanisms of resistance to these mutant-specific drugs have been reported. Moreover, changes in the TME that induce an immunosuppressive state have also been associated with resistance to these drugs^87–89.

Resistance to KRAS inhibition

Although KRAS is no longer undruggable, KRAS inhibitor monotherapy is far from curative. Indeed, plasticity and genetic instability enable tumours to develop resistance to all single-agent targeted therapies^90–92, with KRAS-directed therapies proving no exception. The updated data from the pivotal trial that led to the approval of sotorasib for KRAS^G12C-mutant NSCLC, as an example, show an ORR of only ~41% and median PFS of only 6.3 months, as well as 2-year OS of ~30%⁷⁷. Combining inhibitors of the same pathway (termed ‘vertical inhibition’) has the potential to improve survival outcomes, as perhaps best illustrated by BRAF and MEK inhibitor combinations for melanoma⁹³, but resistance remains inevitable. Targeting parallel pathways (‘horizontal combination’) also invariably leads to resistance or unacceptable toxicity^94,95. Here, we describe emerging data on mechanisms of resistance to single-agent KRAS^G12C inhibitors. Tumour cell-autonomous, as well as non-autonomous (for example, TME-mediated) resistance has been reported, and can be further categorized as being intrinsic (primary) or acquired. Acquired resistance can be further divided into mutational escape of KRAS itself or activation of upstream or downstream mediators. We also discuss potential strategies for overcoming resistance.

Primary resistance

Primary resistance to direct inhibitors of KRAS could theoretically result from mutational heterogeneity in a tumour or the presence of specific co-mutations. Understanding these mechanisms of resistance is crucial to developing informed treatment strategies. KRAS-mutation heterogeneity has been described between different sites of disease in patients with CRC and might, at least in part, explain the variable responses to EGFR-directed therapy in such patients⁹⁶. Similar heterogeneity between tumour sites has been reported in patients with NSCLC^97,98; however, pre-treatment intratumour heterogeneity of KRAS mutations seems to be uncommon⁹⁹. Zhao et al.¹⁰⁰ evaluated 8,750 pre-treatment KRAS-mutant tumour specimens (from 7,790 patients) and found more than one RAS mutation in only 304 specimens (3.5%); among KRAS^G12C-mutant tumours specifically, secondary RAS mutations were found in 3% (40 of 1,432). Cannataro et al.¹⁰¹ performed deep sequencing of 27 KRAS^G12-mutant NSCLCs and found no evidence for pre-existing resistance mutations in KRAS or downstream genes before KRAS^G12C-inhibitor treatment. Knowledge of the mechanisms of primary resistance to KRAS^G12C inhibitors remains extremely limited, and large-cohort multi-omics analyses will be required to identify pre-treatment factors associated with non-responsiveness to these agents.

Acquired resistance due to mutational escape

Mutational escape refers to resistance mutations that develop ‘de novo’ on treatment, being undetectable before therapy. The binding site for the commonly used KRAS inhibitors sotorasib and adagrasib is formed by the amino acid residues at positions 12, 68, 95 and 96 of KRAS^G12C; therefore, mutations that affect these residues are particularly relevant to resistance^68,102,103. For example, acquired second-site Y96D mutations in KRAS^G12C confer clinical resistance to adagrasib by altering the switch 2 pocket such that the inhibitor can no longer bind⁶⁹. In vitro experiments by Koga et al.¹⁰⁴ identified 12 distinct secondary KRAS mutations after treatment of KRAS^G12C-mutant Ba/F3 cells with sotorasib or adagrasib. KRAS^Y96D or KRAS^Y96S mutation conferred resistance to both agents, but both mutations were associated with sensitivity to the SOS1 inhibitor BI-3406 in combination with the MEK inhibitor trametinib (although monotherapy or combination therapy with BI-3406 and/or the SHP2 inhibitor TNO155 was not efficacious)¹⁰⁴. Interestingly, cells with secondary G13D, R68M, A59S or A59T mutations in KRAS remained sensitive to adagrasib despite showing sotorasib resistance¹⁰⁴. Conversely, second-site Q99L mutants were sensitive to sotorasib but resistant to adagrasib¹⁰⁴. These findings demonstrate that although sotorasib and adagrasib are similar compounds, they cannot be considered interchangeable. Perhaps unsurprisingly, given its distinct mechanism of action as a KRAS-on inhibitor, RM-018 retains activity against KRAS^G12C/Y96D (ref.⁶⁹).

In a biomarker analysis of the CodeBreaK 100 trial, plasma next-generation sequencing at baseline and at the time of disease progression revealed heterogeneous acquired molecular alterations in 19 (28%) of 67 patients with NSCLC and in 33 (73%) of 45 patients with CRC following sotorasib monotherapy, with RTK-pathway alterations being most common¹⁰⁵. Secondary RAS alterations were found more commonly in patients with CRC than in those with NSCLC (16% versus 3%, respectively)¹⁰⁵. In the aforementioned study by Zhao et al.¹⁰⁰, treatment-emergent alterations were identified in 27 (63%) of 43 patients receiving sotorasib, consisting of diverse gene amplifications (of KRAS, MET, RICTOR, MYC, MET or FGFR2), mutations (in KRAS, BRAF, NRAS, PTEN, IDH1, IDH2, TP53, EGFR, KEAP1, NF1 and CTNNB1) and deletions (loss of PTEN and CDKN2A/CDKN2B). Secondary KRAS alterations (V8L, G12D/F/V, V14I or Q61H mutation, or gene amplification) were identified in 7 (16%) of the 43 patients. Patient-derived xenograft and cell-line models were subsequently used to show that KRAS^G12V, as well as KRAS^G13D, NRAS^Q61K, NRAS^G13R, MRAS^Q71R or BRAF^G596R mutations, conferred resistance to KRAS^G12C inhibition¹⁰⁰. Similarly, Awad et al.¹⁰⁶ studied baseline and post-treatment samples from 38 patients who developed resistance to adagrasib and found alterations suggestive of various mechanisms of resistance in 17 (45%). These alterations included secondary KRAS mutations (G12D/R/V/W, G13D, Q61H, R68S, H95D/Q/R or Y96C) in nine patients (23%); KRAS^G12C and MET amplifications; activating mutations in NRAS, BRAF, MAP2K1 and RET; oncogenic fusions involving ALK, RET, BRAF, RAAF1 and FGFR3; and loss-of-function mutations in NF1 and PTEN¹⁰⁶. Notably, in vitro validation studies confirmed that R68S, H95D/Q/R and Y96C second-site mutations affecting the switch 2 pocket of KRAS^G12C result in resistance to adagrasib¹⁰⁶. By contrast, the G12C/H95D, G12C/H95Q and G12C/H95R double mutants remained sensitive to sotorasib, suggesting the potential for benefit from this agent in some patients with resistance to adagrasib (although co-existing cross-resistance mechanism might be common). Feng et al.¹⁰⁷ performed a mutagenesis screen of >3,500 missense mutations in KRAS^G12C using the H358 cell line (containing KRAS^G12C in one allele and KRAS^WT in the other) and found that secondary C12F, R68S, H95D/R and Y96C mutations were strongly associated with resistance to KRAS inhibitors¹⁰⁷, consistent with the clinical findings of Awad and colleagues¹⁰⁶. As clinical use of KRAS inhibitors expands and more patients undergo molecular testing at the time of disease progression, these and other similar alterations should be more easily studied and their relative frequency better defined.

Adaptive resistance

Attempts have also been made to target KRAS-mutant cancers by inhibiting upstream and downstream pathway components; however, alterations in these mediators, as well as a type of intrinsic resistance termed ‘adaptive resistance’, inevitably result in a lack of efficacy, and recurrence and progression of these tumours^5,90,91,108. Adaptive resistance refers to the rapid reactivation of the RAS–MAPK pathway at some level, typically as a result of derepression of MYC target genes, such as those encoding RTKs and their ligands, upon suppression of ERK activity¹⁰⁹. Initially described with BRAF and MEK inhibitors^108,109, several studies have shown that similar pathway reactivation occurs upon KRAS^G12C-inhibitor treatment^50,110–113. The precise mechanisms that underlie adaptive resistance to KRAS^G12C inhibitors remain a subject of controversy and seem to differ in at least some respects from those that occur with BRAF and MEK inhibition. For example, the group led by Lito¹¹⁰ hypothesizes that induction of new KRAS^G12C proteins at the transcriptional level and a subsequent KRAS-GTP rebound have an important role in adaptive resistance to KRAS^G12C inhibitors, whereas others groups did not find such upregulation^50,111,112. Indeed, whether adaptive resistance is mediated by reactivation of mutant KRAS or activation of the remaining wild-type KRAS, HRAS and/or NRAS remains unclear^110–112. In this regard, Ryan et al.¹¹² described adaptive resistance to sotorasib and ARS-1620 resulting from activation of wild-type NRAS and HRAS in KRAS^G12C-mutant lung, colon and pancreatic cancer cell lines. Also uncertain is whether adaptive resistance alone can eventually result in regrowth of KRAS^G12C-mutant tumours, without secondary genetic and/or epigenetic alterations, or if this phenomenon instead enables tumour cells to survive until such alterations transpire.

EMT and adeno–squamous transformation

Epithelial-to-mesenchymal transition (EMT) is another potential mechanism of both intrinsic and acquired resistance to KRAS^G12C inhibitors. During EMT, cells downregulate expression of epithelial genes and upregulate expression of mesenchymal ones, gaining increased mobility and invasiveness¹¹⁴. EMT is not unique to KRAS-mutated cancers. For example, the process has been described in patients with EGFR-mutant NSCLC after treatment with EGFR inhibitors¹¹⁵ and results in resistance to these agents, which seems to be mediated by TGFβ¹¹⁶. Seminal work by Singh et al.¹¹⁷ identified a gene-expression signature of KRAS dependency in KRAS-mutant cell lines and demonstrated that loss of expression of certain signature genes was associated with EMT. Moreover, induction of EMT seemed to decrease KRAS dependency¹¹⁷, supporting the idea that EMT can confer resistance to KRAS inhibition. Adachi et al.¹¹⁸ used gene set-enrichment analyses to demonstrate EMT as a mechanism of both intrinsic and acquired resistance to sotorasib. The PI3K pathway was found to be activated in EMT-induced KRAS^G12C-mutant cell lines via bypass IGFR–IRS1 pathway signalling, and combining sotorasib with the PI3K inhibitor GDC-0941 blocked AKT activation and suppressed cellular proliferation¹¹⁸. Adachi and colleagues¹¹⁸ also found that combining sotorasib, GDC-0941 and the SHP2 inhibitor tool compound SHP099 potently inhibited both AKT and ERK activation, resulting in regression of tumours with acquired resistance to sotorasib in mouse models. These preclinical observations and combination strategies warrant further clinical investigation.

Adeno–squamous transformation, a change in histology from adenocarcinoma to squamous cell carcinoma, has been observed in two (22%) of nine patients with KRAS^G12C-mutant NSCLC following acquired resistance to adagrasib, in the absence of genomic resistance mechanisms described previously¹⁰⁶. Similar histological transformation has been associated with resistance to EGFR inhibitors^119,120.

Overcoming KRAS^G12C inhibitor resistance

Vertical combinations

Several strategies to limit adaptive resistance and prolong responses to KRAS^G12C inhibitors are being explored. Although adaptive resistance typically involves the upregulation of several RTKs and RTK ligands, one or more RTK–ligand combinations can predominate in individual tumours. In NSCLCs and CRCs, KRAS^G12C inhibition leads to an accumulation of activated upstream EGFR and/or other ERBB family members, which facilitates escape from KRAS^G12C-inhibitor monotherapy^{110,121–124}. Accordingly, combined KRAS^G12C and EGFR inhibition is currently under investigation in several clinical trials (Fig. 1 and Supplementary Table 1). In CodeBreaK 101 (NCT04185883), sotorasib is being combined with the EGFR/HER2 tyrosine kinase inhibitor afatinib, or with the anti-EGFR monoclonal antibody panitumumab (with or without FOLFIRI chemotherapy)¹²⁵. Data on the sotorasib–afatinib combination from CodeBreaK 101 were presented in late 2021 and showed a manageable safety profile, with the most common treatment-related adverse effects (TRAEs) being diarrhoea and nausea (in 69.7% and 21.2% of patients, respectively, grade ≥3 in 21.2% and 0%)¹²⁶. An efficacy signal was observed with ORRs of 20.0% and 34.8% and DCRs of 70.0% and 73.9% across two dose cohorts, including stable disease in three of five patients who had previously received sotorasib monotherapy¹²⁶. Adagrasib is being combined with cetuximab, another anti-EGFR monoclonal antibody, in KRYSTAL-1 and KRYSTAL-10 (NCT03785249 and NCT04793958, respectively); KRYSTAL-1 is also investigating adagrasib in combination with afatinib for the treatment of NSCLC specifically. GDC-6036 is also being tested in combination with cetuximab as well as with the EGFR tyrosine kinase inhibitor erlotinib (NCT04449874).

Since its discovery in 1992 (ref.¹²⁷), SHP2 has emerged as a key ‘positive’ upstream regulator of the RAS–MAPK pathway and thus an essential component of signalling by multiple oncogenic driver kinases (Fig. 1), as well as a complex positive and negative regulator of immune cell signalling^128–132. SHP2 is required for tumorigenesis in several models of KRAS-mutant NSCLC^133,134, suggesting that SHP2 inhibition could have a role in the treatment of KRAS-mutant cancers. SHP2 also has KRAS-independent effects on JAK–STAT signalling, which might mediate aspects of immune-checkpoint receptor action⁵⁰. Highly selective, potent, bioavailable inhibitors of SHP2 are now in clinical testing (Table 1 and Supplementary Table 1), after many years of preclinical development¹²⁸. These agents inhibit RAS GDP–GTP exchange (Fig. 1) and, accordingly, have single-agent activity against cycling KRAS mutants, especially KRAS^G12C, in preclinical models⁵⁰. Furthermore, studies using the SHP2 inhibitor RMC-4550 have shown that class III BRAF-mutant, NF1-mutant and select RAS-mutant cancers remain dependent on SHP2 function¹³⁵. The fact that SHP2 acts downstream of RTKs and upstream of SOS1/2 in the RAS signalling pathway makes this GEF an attractive target for preventing adaptive resistance to KRAS^G12C inhibitors. Misale et al.¹¹³ demonstrated that the mechanism by which KRAS^G12C-mutant NSCLC cells develop adaptive resistance to ARS-1620 involves reactivation of the MAPK pathway facilitated by incomplete inhibition of PI3K–AKT signalling. As well as discovering the role of wild-type RAS in this adaptive resistance, Ryan et al.¹¹² demonstrated that the activation of wild-type RAS could be suppressed through co-inhibition of KRAS with ARS-1620 and SHP2 with SHP099. Fedele et al.⁵⁰ reported similar findings in cell lines, extending their observations to immunocompetent mouse models of pancreatic and lung cancer.

SHP2 and KRAS co-inhibition not only alters cancer cell signalling, but also has important effects on the TME. Specifically, the studies by Fedele et al.⁵⁰ in syngeneic orthotopic and subcutaneous KRAS^G12C-mutant tumours revealed depletion of myeloid-derived suppressor cells (MDSCs) and enrichment of cytotoxic T cells in the TME, which was associated with increased sensitivity to PD-1 blockade. Differences were noted in the effects of SHP099 alone and in combination with ARS-1620 in models of PDAC and NSCLC, including variations in the relative contribution of SHP2 inhibition in cancer cells and cells of the TME between the models⁵⁰. The findings of this study emphasize the importance of considering not only cell of origin, but also the injection site (subcutaneous or orthotopic) and the precise tumour genetics.

On the basis of the improved efficacy of combined SHP2 and KRAS inhibition in preclinical studies, TNO155 is currently under investigation in combination with adagrasib in the KRYSTAL-2 trial (NCT04330664)¹³⁶ and with sotorasib in CodeBreak 101 (NCT04185883), as well as with JDQ443 in KontRASt-01 (NCT04699188). CodeBreaK 101 is also testing the combination of sotorasib with RMC-4360 (a SHP2 inhibitor similar to RMC-4550)¹²⁵. Several other clinical trials are evaluating combinations of various SHP2 and KRAS^G12C inhibitors (Supplementary Table 1).

Indirect targeting of RAS via SOS1 constitutes another form of vertical inhibition of this signalling pathway. SOS1 and its paralogue, SOS2, are crucial RAS-GEFs; thus, SOS1/2 inhibition presents a different strategy for suppressing the activity of RAS mutants that retain at least some capacity to undergo GTP hydrolysis, either through intrinsic or GAP-stimulated GTPase activity (Fig. 1). BI-3406 is an orally available small-molecule inhibitor that binds selectively within the active site of SOS1 (but not SOS2) and disrupts its interaction with RAS-GDP. SOS1 activation has been shown to be a key mechanism of adaptive resistance to MEK inhibitors; therefore, BI-3406 has been evaluated in combination with trametinib in KRAS^G12C-mutant and KRAS^G13D-mutant cell lines and found to synergistically inhibit their growth⁷⁵. Indeed, given that SOS1 inhibitors affect KRAS interactions, they might be active across many KRAS mutations, including G12C, G12V, G12S, G12A and G12D, but notably not G12R as this variant does not bind to the catalytic domain of SOS1 (ref.¹³⁷). In preclinical studies, BI-3406 decreased cellular proliferation in a range of KRAS-mutant NSCLC, PDAC and colon cancer cell lines¹³⁷. Interestingly, BI-3406 was more effective in decreasing RAS-GTP levels and in arresting cellular proliferation in SOS2-knockout models, suggesting SOS2 induction as a potential resistance mechanism; however, no (immediate) upregulation of SOS2 mRNA levels was observed¹³⁷. BI 1701963, a similar small molecule to BI-3406, also impairs KRAS–SOS1 binding¹³⁸ and has preclinical activity in inhibiting KRAS with activating mutations¹³⁹. This agent has entered early phase clinical trials as monotherapy (NCT04111458) as well as in combination with the KRAS^G12C inhibitors adagrasib (KRYSTAL-14; NCT04975256) and BI 1823911 (NCT04973163) (Table 1 and Supplementary Table 1). Another SOS1 inhibitor, BAY-293, has been shown to have activity against KRAS^G12C-mutant cell lines when combined with the KRAS^G12C inhibitor ARS-853 (ref.¹⁴⁰). BAY-293 also has demonstrated cytotoxicity against other KRAS-mutant NSCLC and PDAC cell lines, and synergy with MEK, CDK4/6, topoisomerase I or EGFR inhibitors¹⁴¹.

The merits of targeting SOS1 should be considered in the context of strategies that target SHP2 (ref.¹⁴²). SHP2 is required for full activation of SOS1/2, whereas SOS1 inhibitors are inactive against SOS2. Therefore, on the one hand, SHP2 inhibition could be viewed as superior to SOS1 inhibition. On the other hand, SOS1 inhibitors target RAS GDP–GTP exchange directly, whereas SHP2 is indirectly required for this process and thus might be susceptible to bypass mechanisms. Notably, however, SHP2 inhibition has the potential to induce favourable effects within the TME, such as depletion of MDSCs and enhancement of cytotoxic lymphocytes via actions on the IL-6–JAK–STAT3, TNF and IFNγ signalling pathways⁵⁰, which are not directly regulated by SOS1. Preclinical studies that directly compare SHP2 and SOS1 inhibitors in immunocompetent models are warranted, although ultimately, this theoretical argument will be best resolved in clinical trials. Furthermore, on-target, off-tumour toxicity is another important consideration with both SOS1 and SHP2 inhibitors that will be evaluated in clinical trials.

The CodeBreaK 101 trial is also evaluating trametinib in combination with sotorasib, with or without panitumumab, in patients with various KRAS^G12C-mutant solid tumours (NCT04185883; Supplementary Table 1). The rationale for this combination is predicated on evidence that KRAS-mutant tumour cells are inherently resistant to MEK inhibitors owing to RAF-mediated MEK activation (Fig. 1), which might be abrogated by simultaneous inhibition of mutant KRAS^143,144. Preliminary results from 41 patients receiving sotorasib plus trametinib in CodeBreak 101, including 18 with NSCLC and 18 with CRC, were presented in late 2021 (ref.¹⁴⁵). The combination was found to be safe and tolerable, with predominantly grade ≤2 diarrhoea (in 43.9% of patients), rash (34.1%), nausea (29.3%) and vomiting (22.0%) being the most commonly reported TRAEs¹⁴⁵. This combination was associated with clinical benefit in 15 patients with CRC and 15 with NSCLC, including two and three PRs, respectively¹⁴⁵. Importantly, even patients previously treated with a KRAS^G12C inhibitor derived clinical benefit (including a PR in the CRC cohort)¹⁴⁵. Additionally, the aforementioned SOS1 inhibitor, BI 1701963, is also being evaluated with trametinib in a phase I trial (NCT04111458; Supplementary Table 1), based on a similar mechanistic rationale.

Horizontal combinations

Inhibition of mTOR has been proposed as an alternative strategy to overcome adaptive resistance to KRAS (or MEK) inhibitors (Fig. 1). In several preclinical models of PDAC, resistance to KRAS or MEK inhibition purportedly occurs through bypass signalling via increased integrin-linked kinase (ILK)-mediated phosphorylation of Rictor, a component of the mTOR complex 2 (mTORC2), and subsequent mTORC2-mediated phosphorylation of AKT. Accordingly, co-inhibition of KRAS^G12C or MEK and mTORC1/2 synergistically impaired ERK and AKT activation, resulting in durable inhibition of PDAC growth and metastasis in mouse models¹⁴⁶. In CodeBreak 101, the mTOR inhibitor everolimus is being evaluated in combination with sotorasib (NCT04185883; Supplementary Table 1).

Cell-cycle inhibition provides another potential horizontal combination strategy for synergy with KRAS inhibitors (Fig. 1). CDK4/6 inhibitors, such as palbociclib, ribociclib and abemaciclib, are effective in the treatment of some cancers, particularly oestrogen receptor-positive breast cancers¹⁴⁷. These inhibitors impair cell-cycle progression driven by D-type cyclins¹⁴⁸, which are a convergent node of the RAS–MAPK and PI3K–AKT pathways. Moreover, in vitro and in vivo preclinical studies suggest additive and synergistic benefit of CDK4/6 and KRAS^G12C co-inhibition in models of NSCLC and PDAC¹⁴⁹. CodeBreak 101 is testing this concept in patients by combining sotorasib with palbociclib (NCT04185883; Supplementary Table 1).

Aurora kinases (AURKA, AURKB and AURKC) have crucial cell-cycle regulatory functions that support mitotic progression, and dysregulation of these kinases seems to promote tumorigenesis by both enhancing cell proliferation when activated and contributing to aneuploidy when dysfunctional¹⁵⁰. Furthermore, AURKA expression is a poor prognostic indicator in patients with NSCLC¹⁵¹. Aurora kinase signalling has also been implicated in KRAS-mutant malignancies, and these kinases are upregulated by mutant KRAS in NSCLC cell lines¹⁵². Knockdown of AURKA or dual inhibition of AURKA and AURKB has antitumour activity in preclinical models involving such cell lines¹⁵². In keeping with the intertwined roles of AURKA and KRAS, AURKA activity seems to be a mechanism of not only adaptive but also intrinsic and acquired resistance to KRAS inhibition, with increased expression of AURKA seen in sotorasib-resistant cell lines¹⁵³. In preclinical models, combined inhibition of AURKA and KRAS^G12C showed synergy¹¹⁰. Moreover, the selective AURKA inhibitor VIC-1911 and sotorasib had synergistic activity in KRAS-mutant NSCLC cell lines intrinsically resistant to sotorasib, presenting a viable strategy to negate resistance to KRAS^G12C inhibitors¹⁵³.

The mitotic checkpoint kinase WEE1 is another important cell-cycle regulator and target for cancer therapy¹⁵⁴. The multi-kinase inhibitor sorafenib has poor activity in KRAS^G12V-mutant cell lines, and high-throughput screening identified WEE1 as a potential modulator of sorafenib response that could be targeted pharmacologically (with the WEE1 inhibitor adavosertib)¹⁵⁵. Given these interactions, the role of WEE1 has been evaluated in models of acquired resistance to KRAS^G12C inhibitors, with synergistic activity of adavosertib and VIC-1911 against sotorasib-resistant NSCLC cells in vitro and in vivo, suggesting the potential therapeutic utility of this approach¹⁵³.

Immune-mediated escape and immunotherapy combination strategies

Mutant KRAS, like other driver oncogenes, has effects on cells of the TME, in addition to altering the behaviour of cancer cells themselves^87,156 (Fig. 3). Accordingly, mutant-selective KRAS inhibitors can have indirect effects on immune cells, fibroblasts and endothelial cells in the TME (including the lymphatic epithelium) by reversing the actions of mutant KRAS^87,156 — albeit mitigated by adaptive and acquired resistance. Other agents that target RAS signalling, presumably including pan-RAS inhibitors, are likely to have additional direct effects on cells of the TME, which might vary by tumour type and location (for example, primary versus metastatic). A detailed understanding of these pleiotropic actions could facilitate the rational design of curative combinations.

Fig. 3. The influence of mutant KRAS on the tumour immune microenvironment.

Activating KRAS mutations have numerous implications for the tumour immune microenvironment^87,156, including activation and recruitment of macrophages, polarization of M1 to M2 macrophages, and suppression of CD8⁺ T cells via effects on MHC–T cell receptor (TCR) and PD-L1–PD-1 signalling as well as via activation of myeloid-derived suppressor cells (MDSCs) and regulatory T (T_reg) cells. Together, these alterations in the tumour microenvironment present opportunities for intervention in the treatment of KRAS-mutated malignancies, and pertinent examples are provided. DC, dendritic cell; ICAM1, intercellular adhesion molecule 1.

KRAS has multiple immunomodulatory effects, mediated via several mechanisms (Fig. 3). Activation of KRAS increases production of the neutrophil chemoattractants CXCL1, CXCL2 and CXCL5; promotes recruitment of pro-inflammatory M1 macrophages via upregulation of intercellular adhesion molecule 1 (ICAM1) expression (conversely, co-activation of KRAS and MYC increases anti-inflammatory M2 macrophage recruitment via release of CCL9 and IL-23); induces immunosuppressive regulatory T (T_reg) cell differentiation via secretion of TGFβ and IL-10; and enhances tumour infiltration of MDSCs via GM-CSF-dependent and IRF2/CXCL3-dependent mechanisms^87,156. Additionally, Ischenko et al.¹⁵⁷ used CRISPR–Cas9-mediated gene editing in PDAC models to demonstrate a key role of mutant KRAS in tumour immune evasion, which was attributed to alterations in both the cancer cells themselves and immune cells, and also implicated downstream BRAF and MYC signalling in this process. Accordingly, loss of oncogenic KRAS or BRAF abrogated tumour growth in immunocompetent syngeneic mice¹⁵⁷.

The aforementioned study by Fedele et al.⁵⁰ demonstrated that SHP2 inhibition is synergistic with KRAS^G12C inhibition through cancer cell-autonomous mechanisms as well as distinct effects on the TME in models of PDAC and NSCLC. Using PDAC cells expressing drug-resistant SHP2, these researchers demonstrated that all of the effects on immune components of the TME were dependent on inhibition of SHP2 in tumour cells; however, SHP2 inhibitors had direct anti-angiogenic actions in this model⁵⁰. A subsequent study confirmed and extended these findings, implicating SHP2 inhibitors in suppression of VEGFR signalling¹⁵⁸. By contrast, in the NSCLC model, substantial effects on the TME were observed even when SHP2 could not be inhibited in tumour cells; remarkably, SHP2 inhibition enhanced lung tumour vascularity, instead of reducing it⁵⁰.

Building on these findings, Tang et al.¹⁵⁹ found that in genetically engineered mouse models, SHP2 inhibition in KRAS-mutated or EGFR-mutated NSCLCs depleted alveolar and M2-like macrophage populations, increased T cell and B cell infiltration, but also enhanced accumulation of potently immunosuppressive granulocytic MDSCs (gMDSCs). The latter effect was attributable to NF-κB-induced secretion of the neutrophil lineage chemoattractants CXCL1 and CXCL5 (among other chemokines) by tumour cells¹⁵⁹. Remarkably, production of these chemokines and subsequent CXCR2-dependent gMDSC infiltration required SHP2 inhibition in tumour cells, whereas the effects on lymphocytes, macrophages and monocytic MDSCs occurred even when tumour cells could not respond to the inhibitor¹⁵⁹. These findings suggest that oncogenic KRAS promotes immune escape by fostering an immunosuppressive TME that can be mitigated through SHP2 inhibition — albeit subject to resistance mediated by CXCR2 signalling, which could potentially be a target of combinatorial strategies¹⁵⁹ (Fig. 3).

ICIs, including those that target PD-1/PD-L1 and CTLA4, have shown efficacy in treating various cancers, most prominently NSCLC and melanoma¹⁶⁰. Indeed, ICIs are the standard-of-care first-line treatment for advanced-stage NSCLCs that lack targetable oncogenic mutations, with or without chemotherapy depending on tumoural PD-L1 expression level¹⁶¹. As a result of the first-line approvals, many patients with KRAS-mutant NSCLCs will receive ICIs, given that sotorasib is currently approved only as a second-line treatment. Considering the various mechanisms by which mutant KRAS has direct and indirect immunomodulatory effects, particularly as they pertain to cytotoxic T cell activity, combining KRAS inhibitors with ICIs is a rational strategy. In mouse models of KRAS^G12C-mutant tumours treated with sotorasib, pro-inflammatory changes were seen within the TME, and combination therapy with ICIs resulted in synergistic tumour cell killing¹⁰². Furthermore, mice cured with a combination of sotorasib and an anti-PD-1 antibody rejected isogenic KRAS^G12C and KRAS^G12D cells upon re-challenge, suggesting adequate memory immune cell responses against common antigens¹⁰². Briere et al.¹⁶² demonstrated that adagrasib induces MHC class I (MHC I) expression and promotes a pro-inflammatory state in human KRAS^G12C-mutant tumour cell xenografts. Moreover, adagrasib depleted intratumoural MDSCs while increasing cytotoxic immune cell infiltration in syngeneic mouse models; tumour responses were observed in these immunocompetent BALB/c mice, but were attenuated in T cell-deficient mice¹⁶². Furthermore, combination treatment with adagrasib and an anti-PD-1 antibody resulted in durable antitumour responses, again, with evidence of immunological memory responses¹⁶². Of note, however, both of these studies used subcutaneous syngeneic models, the clinical relevance of which is uncertain. Nevertheless, this approach of combining a KRAS^G12C inhibitor with an ICI is being evaluated in several clinical trials across KRAS^G12C-mutant solid tumours (Supplementary Table 1), including with sotorasib in CodeBreaK 100 (NCT03600883) and CodeBreaK 101 (NCT04185883), adagrasib in KRYSTAL-1 (NCT03785249) and KRYSTAL-7 (NCT04613596), GDC-6036 in GO42144 (NCT04449874) and JDQ443 in KontRASt-01 (NCT04699188).

RAS-driven cancers rely on autophagy for survival¹⁶³, and this complex cellular process also seems to have immunomodulatory effects that promote tumour immune evasion. In models of KRAS^G12D-mutant PDAC, MHC I is degraded in an autophagy-dependent manner, with inhibition of autophagy enhancing MHC I expression, antigen presentation, cytotoxic T cell activation and subsequent antitumour immunity¹⁶⁴. Moreover, ICIs were found to have encouraging efficacy in these models when combined with autophagy inhibition¹⁶⁴. Additionally, MEK and autophagy inhibitors have synergistic activity against PDAC cell lines¹⁶⁵. These data highlight the complex interplay of mediators in KRAS-driven cancers but also point towards vulnerabilities that can be exploited.

As noted previously, Tang et al.¹⁵⁹ discovered that RAS–MAPK pathway inhibition can result in CXCL1/CXCL5-dependent infiltration of KRAS-mutant NSCLCs by gMDSCs, depletion of which markedly increases accumulation of cytotoxic CD8⁺ T cells in the TME. Using their mouse models, these researchers also demonstrated that tumour control was markedly improved by combining SHP2 and/or EGFR inhibitors with SX-682, a novel oral small-molecule inhibitor of CXCR1 and CXCR2. The mice were not cured, however, potentially owing to T cell exhaustion mediated by PD-1 and/or by two other inhibitory immune-checkpoint receptors, NKG2A and/or KLRG1, which were found to be expressed on the CD8⁺ T cells. Notably, data from various mouse models indicate that disrupting the CXCR1/2–MDSC axis in tumours is therapeutically efficacious across a wide variety of solid cancers^166–172. By reversing MDSC-mediated immunosuppression, SX-682 is also predicted to unmask greater efficacy of chemotherapy and immunotherapies (such as anti-CTLA4 and anti-PD-1 antibodies) that act by mechanisms that are non-redundant and indeed complementary to those of CXCR1/2 antagonists¹⁷³. Tang et al.¹⁵⁹ also showed that adagrasib increased CXCL1 and CXCL6 mRNA levels (both encoding ligands of CXCR1/2) in KRAS^G12C-mutant cell lines, as well as tumour infiltration by gMDSCs in preclinical models. Furthermore, analyses of matched pre-treatment and post-treatment biopsy samples provided evidence of these effects of adagrasib in patients with NSCLC¹⁵⁹, highlighting the promise of combining CXCR1/2 inhibitors with KRAS inhibition.

Extending the breadth of RAS inhibitors

KRAS-on inhibitors

Given that KRAS^G12D has lower intrinsic GTPase activity than KRAS^G12C, most KRAS^G12D proteins will be GTP bound. Thus, agents that target KRAS^G12D-GTP, as well as other RAS isoforms (RAS-on inhibitors; Fig.1), have been a focus of drug development. In 2020, Zhang et al.¹⁷⁴ identified three cyclic peptide ligands that are unique in that they bind preferentially within the switch 2 groove of KRAS^G12D-GTP and inhibit its interaction with RAF proteins. Notably, these compounds have no discernable effect on wild-type KRAS, exemplifying the distinct features of the GTP-bound state of KRAS mutants¹⁷⁴. By contrast, the crystal structure of KRAS^G12D-GDP in a complex with KRpep-2d revealed that this KRAS^G12D-selective inhibitory peptide binds to a region near switch 2 and competes with GEF binding¹⁷⁵. In 2021, Wang et al.¹⁷⁶ reported the discovery and characterization of MRTX1133 as a noncovalent, selective KRAS^G12D inhibitor. MRTX1133 binds to the switch 2 pocket of GDP-bound KRAS^G12D as well as GTP-bound KRAS^G12D and was shown to successfully arrest KRAS-mediated signalling, resulting in substantial tumour regression in mouse xenograft models¹⁷⁶. Vasta et al.¹⁷⁷ have used NMR spectroscopy and competitive bioluminescence resonance energy transfer (BRET)-based engagement assays to demonstrate that the switch 2 pocket of several other non-G12C mutants of KRAS can be targeted in a noncovalent manner that is not reliant on the protein being GDP bound.

Thus, most small-molecule inhibitors of mutant KRAS currently in clinical development target the expanded pocket near the switch 2 region. However, an alternative and unique approach of targeting a switch 1/2 pocket is currently being evaluated. This pocket was initially described by Kessler et al.^178,179 during the development of BI-2852, a small molecule that induces nonfunctional dimerization of KRAS. This approach offers the advantage, shared by MRTX1133, of targeting both the GTP-bound and GDP-bound states of KRAS^178,179. Notwithstanding, successful clinical application of this approach remains to be reported.

Another novel strategy for targeting mutant KRAS and/or other mutant RAS isoforms, originally conceived by the group of G. Verdine¹⁸⁰, uses a mechanism analogous to that of the immunosuppressants cyclosporin, FK506 and rapamycin. Cyclosporin binds to the chaperone protein cyclophilin A (also known as peptidyl-prolyl cis-trans isomerase A), and the cyclosporin–cyclophilin complex in turn binds to and inhibits the serine/threonine phosphatase calcineurin. FK506 binds to a different chaperone, FKBP12, although the resultant complex also inhibits calcineurin. Rapamycin also interacts with FKBP12, but the rapamycin–FKBP12 complex binds to and inhibits mTORC1 (ref.¹⁸¹). Various compounds that bind to cyclophilin A and subsequently form inhibitory trimeric complexes with various RAS proteins have been developed. For example, RM-018 is a covalent KRAS^G12C inhibitor, but through its interaction with cyclophilin A, targets KRAS^G12C in the GTP-bound state; hence, RM-018 is a KRAS^G12C-on inhibitor⁶⁹. Preclinical data on the later-generation ‘tri-complex’ KRAS^G12C-on inhibitor, RMC-6291, were presented in April 2022 and suggest superiority over the KRAS-off inhibitor adagrasib¹⁸², supporting the viability of this targeting approach. Other tri-complex agents that target specific KRAS mutants in their GTP-bound state include RMC-9805 (KRAS^G12D) and RMC-8839 (KRAS^G13C). Moreover, pan-RAS-mutant targeting might also be possible using this tri-complex strategy, as exemplified by RMC-6236. This agent is a RAS^MULTI-on inhibitor that forms tri-complexes with cyclophilin A and several KRAS mutants, with activity against KRAS^G12D, KRAS^G12V and KRAS^G12R mutations demonstrated in preclinical models^183,184. Of note, this compound is also active against ‘RAS oncogene switch’ mutations (within the switch 2 pocket), which confer resistance to adagrasib¹⁰⁶, and it shows synergy with anti-PD-1 antibodies¹⁸⁵.

Tri-complex RAS inhibitors are now entering clinical trials (NCT05379985; Table 1 and Supplementary Table 1); it will be interesting to see whether their impressive preclinical efficacy translates into improved patient outcomes. Importantly, cyclophilin A is expressed ubiquitously¹⁸⁶, and thus diverse RAS-mutant tumour types could be amenable to these agents. Toxicity might be an issue, particularly with RAS^MULTI-on inhibitors, given that the clinical effect of wild-type RAS inhibition at this level is not known. Moreover, mutations in PPIA (which encodes cyclophilin A) could conceivably result in loss of drug binding and/or activity, although such resistance mutations would have to be homozygous, given that tri-complex inhibitors only need to bind to a small fraction of cellular cyclophilin A to fully inhibit their RAS targets. Whether homozygous PPIA mutations are consistent with cell viability remains unclear. It will also be interesting to see whether similar tri-complex strategies can be developed using compounds that bind to FKBP12 or other cellular chaperones, or that target cellular oncoproteins other than KRAS.

RAS degraders and toxins

RAS degraders are another novel approach to targeting RAS-mutant malignancies. Proteolysis-targeted chimeras (PROTACs) promote the proteasomal degradation of disease-associated proteins via bivalent small molecules that bind to and bring together the protein of interest and an E3 ubiquitin ligase. LC-2 is a PROTAC designed to target KRAS^G12C (Table 1). This compound combines adagrasib and a ligand for the E3 ligase VHL, enabling depletion of KRAS^G12C protein and thus attenuation of cellular proliferation in KRAS^G12C-mutant cell lines¹⁸⁷. Similarly designed pan-KRAS¹⁸⁸ and other mutant-specific KRAS degraders¹⁸⁹ are in preclinical development. Given the size and molecular structure of these compounds, oral bioavailability might be limited, constituting a potential challenge of this approach¹⁹⁰.

The use of chimeric toxins is an alternative approach to RAS targeting. RRSP–DT_B is one such agent (Table 1), consisting of a RAS/RAP1-specific endopeptidase (RRSP) derived from the bacillus Vibrio vulnificus combined with translocation B fragment of diphtheria toxin (DT_B)¹⁹¹. This toxin enters cells via heparin-binding EGF-like growth factor (HB-EGF)-mediated endocytosis and subsequently cleaves RAS within the switch 1 region¹⁹¹. Uniquely, RRSP–DT_B is able to cleave HRAS, NRAS and KRAS irrespective of GTP or GDP binding¹⁹¹. Vidimar et al.¹⁹¹ have shown that this agent inhibits ERK signalling via RAS inactivation in KRAS-mutant PDAC models, resulting in ≥95% tumour regression without evidence of resistance¹⁹¹. Notably, when studied in immunocompetent mice, the toxin was not detectable in serum at 16 hours after administration, suggesting the need for frequent dosing¹⁹¹. Furthermore, efforts to increase the selectivity of RRSP uptake into malignant cells are currently under way¹⁹¹ and might improve the toxicity profile of this agent.

Immunotherapies targeting KRAS

Adoptive cell therapy (ACT), pioneered by the Rosenberg laboratory, involves isolating immune cells, typically tumour-infiltrating lymphocytes (TILs), expanding them ex vivo and then reintroducing them into the patient. This approach, initially used in patients with melanoma¹⁹², has more recently been extended to several other cancer types, including KRAS-mutant tumours. Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.¹⁹³, who identified CD8⁺ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRAS^G12D. ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRAS^G12D-mutant CRC from whom they had been isolated¹⁹³. Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion¹⁹³.

Other MHC I-restricted mutant KRAS epitopes have since been characterized, presenting opportunities for ACT against various KRAS-mutant malignancies. For example, Bear et al.¹⁹⁴ identified TCRs that recognize G12V–HLA-A*03:01, G12V–HLA-A*11:01 and G12R–HLA-B*07:02 complexes, and further validated this approach by showing that exogenous expression of these TCRs in primary TCRαβ^null cytotoxic T cells redirects their activity towards KRAS-mutant cell lines of various histologies. Furthermore, adoptive transfer of TCR-engineered CD8⁺ T cells specific for G12V–HLA-A*03:01 or G12V–HLA-A*11:01 showed efficacy in xenograft models of metastatic KRAS^G12V-mutant NSCLC¹⁹⁴. ACT with TCR-engineered T cells that target KRAS^G12V-mutant cells has entered clinical trials (Table 1 and Supplementary Table 1).

Therapeutic cancer vaccines constitute another immune-based approach to target KRAS-mutant tumours. mRNA-based vaccine technology has the potential to introduce strong immune responses, as exemplified by the recent success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines¹⁹⁵. mRNA-5671/V941, a liquid nanoparticle-formulated mRNA neoantigen vaccine that targets the G12D, G12V, G13D and G12C variants of KRAS, has been developed and has strong mechanistic rationale¹⁹⁶. On this basis, mRNA-5671/V941 was moved into phase I clinical testing, both as a monotherapy and in combination with PD-1 blockade (NCT03948763; Table 1), although the trial was subsequently closed to enrolment. Additionally, a long-peptide vaccine with activity against the G12C, G12V, G12D, G12A, G13D and G12R variants of KRAS is currently being evaluated in combination with ICIs in a phase I trial (NCT04117087). A dendritic cell-based vaccine that targets G12C, G12D, G12R and G12V neoepitopes of mutant KRAS is also in a phase I trial (NCT03592888; Supplementary Table 1). ELI-002 2P (two peptide) is a novel vaccine consisting of lipid amphiphile (Amph)-modified G12D-mutant and G12R-mutant KRAS peptides with an immunostimulatory Amph-modified CpG oligonucleotide adjuvant (Amph-CpG-7909) that has been shown to result in increased mutant KRAS-specific cytotoxic T cell activity¹⁹⁷. ELI-002 2P is currently being evaluated in the adjuvant treatment of patients with minimal residual disease after standard treatment for KRAS^G12D/G12R-mutant PDACs or other solid tumours (AMPLIFY-201, NCT04853017; Table 1 and Supplementary Table 1). A future iteration of this trial will test ELI-002 7P (seven peptide), a vaccine that contains G12D, G12R, G12V, G12A, G12C, G12S and G13D neoepitopes of KRAS.

Antibody-based therapeutics that target mutant KRAS peptide–MHC complexes have also been proposed. As noted above, peptides derived from KRAS^G12 variants^193,194, and also from KRAS^Q61H/L/R (ref.¹⁹⁸), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules. Bispecific dimeric single-chain antibody fragment constructs, so-called ‘diabodies’, have been engineered to recognize such MHC I–peptide complexes on KRAS-mutant cells and recruit T cells by simultaneously binding to CD3; these agents induced T cell-mediated cytotoxicity in vitro, with some anticancer activity observed in mouse models (although the effect did not reach statistical significance)¹⁹⁸. Whether this approach will be intrinsically limited by the low level of neoepitope presentation remains to be seen. Soluble TCR therapies present an alternative, although related, strategy to bispecific antibodies. Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial¹⁹⁹. A similar approach might be possible for KRAS-mutant tumours. Of note, with all these immunotherapy approaches, the immunosuppressive TME, to which mutant KRAS directly contributes, must be overcome if their efficacy is to be realized.

siRNA-based approaches

Preclinical efforts have been made to develop nanoparticle-based platforms to deliver KRAS-specific small interfering RNAs (siRNAs). This technology has been shown to be adequately delivered to cancer cells and to effectively decrease their KRAS levels, resulting in anticancer activity^200–202 (Table 1). Exosomes are natural nanoparticles and have been engineered to deliver specific siRNAs to downregulate production of mutant KRAS (known as iExosomes) and are under clinical investigation for the treatment of KRAS^G12D-mutant PDAC^203,204 (NCT03608631; Supplementary Table 1). These siRNA-based approaches might circumvent some of the difficulties in drug delivery, with endocytosis resulting in increased concentrations of the active agent being brought to tumour cells, in which this uptake mechanism is typically upregulated. Exosomes are associated with their own delivery challenges, mostly owing to phagocytosis by immune cells, although certain surface markers can be leveraged to mitigate these challenges. Thus, siRNA-based approaches against KRAS-driven cancers might present viable treatment strategies.

Conclusions

Since the identification of KRAS mutations in lung cancer more than three decades ago, KRAS-targeted drug discovery has come a long way, with a plethora of inhibitors, combination approaches and novel alternative targeting methods now under clinical investigation. However, the data on KRAS^G12C inhibitors, which have advanced the furthest in development and are entering clinical practice, emphasize that these agents are far from curative⁶⁷. The modest benefits are attributable, at least in part, to resistance that almost invariably develops with single-agent therapy^90–92. Herein, we have taken a reductionist approach to understanding resistance to KRAS-targeted therapies. However, recent work by Tsai et al.⁸⁸ has revealed the true scope of the challenge ahead. In a rapid autopsy study using RNA and whole-exosome sequencing in a patient with KRAS^G12C-mutant NSCLC that developed resistance to sotorasib, they found that some areas of tumour growth had a decreased allele frequency of KRAS^G12C, others had reactivation of MAPK signalling in the absence of mutations in components of this pathway, while different areas had evidence of EMT and remodelling of the TME, including immune escape⁸⁸. This study provides what is perhaps a much-needed reality check, highlighting the complexity and plasticity of the RAS pathway as well as the likelihood that substantial work lies ahead to further advance KRAS-targeted therapy.

In this Review, we describe strategies for overcoming resistance mechanisms through vertical inhibition of multiple nodes of the RAS pathway, with specific learnings from the saga of combined BRAF and MEK targeting in melanoma, which increases efficacy but is still not curative⁹³. In addition, we describe combination strategies for horizontal inhibition of parallel pathways, an approach also marred by resistance in addition to toxicity^94,95. Most likely, curative strategies will require the induction of a durable antitumour memory immune response via rational and dynamic combination strategies. Lastly, we discuss novel approaches for combating resistance as well as novel treatment strategies that can inject further promise into a field that has ballooned with optimism for the first time in decades, now that KRAS has officially lost its title as ‘undruggable’. We look forward to new approaches capable of achieving this long-sought goal of cure in populations of patients with KRAS-mutant malignancies.

Author contributions

All authors contributed equally to all aspects of the article.

Peer review

Peer review information

Nature Reviews Clinical Oncology thanks F. Skoulidis, T. Yoshino and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Competing interests

V.V. has received fees for consulting or serving on advisory boards from Amgen, AstraZeneca, Bristol Myers Squibb (BMS), EMD Serono, Foundation Medicine, GlaxoSmithKline, Iteos Therapeutics, Merck, Novartis and Novocure. B.G.N. is a co-founder, holds equity in and receives consulting fees from Lighthorse Therapeutics and Navire Pharmaceuticals; is a co-founder and holds equity in Northern Biologics; is a scientific advisory board (SAB) member for, holds equity in and receives consulting fees from Arvinas; and is an SAB member for and holds equity in Recursion Pharma. K.-K.W. is a co-founder of and holds equity in G1 Therapeutics; has received grants from Alkermes, Ansun, AstraZeneca, BMS, Dracen, Merus, Mirati, Takeda and Tvardi; grants and personal fees from Delfi, Janssen, Pfizer and Zentalis; personal fees from Navire, Prelude and Recursion; and grants from Ono outside the submitted work. S.R.P. declares no competing interests.

Supplementary information

The online version contains supplementary material available at 10.1038/s41571-022-00671-9.